mannosidase alpha class 2C member 1Genealiases: CDDG2 · MAN6A8 · MANA · MANA1
Q-omics provides the consensus-scored MAN2C1 profile across patient tissues and cancer cell-line models. MAN2C1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, MAN2C1 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, MAN2C1 protein abundance shows 32,225 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight COAD, LIHC, and LSCC as cancer lineages where MAN2C1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAN2C1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAN2C1 survival associations across molecular data types. MAN2C1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAN2C1 RNA expression–survival associations across cancer types. High MAN2C1 expression shows unfavorable associations in COAD, ACC, UVM, KIRC and MESO, but favorable associations in BRCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify COAD as the clearest survival context for MAN2C1 RNA expression.
This table summarizes MAN2C1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 8. The strongest signals are observed in LIHC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MAN2C1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAN2C1 shows lower tumor expression in BRCA, LUAD and UCEC and higher tumor expression in LIHC, COAD and CHOL. The LIHC box plot shows higher MAN2C1 RNA expression in tumor versus normal tissue (log2 FC = +0.745, t-test p < 0.001).
This table shows molecular features associated with MAN2C1 in patient tissues and cancer cell lines. In patient samples, MAN2C1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MAN2C1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
